share_log

大摩:个体化癌症疫苗和ADC将成为2025年肿瘤治疗行业主要催化剂

Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.

Zhitong Finance ·  Dec 30, 2024 16:51

Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.

According to reports from Zhituo Finance APP, Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADC) will become one of the main innovations in cancer treatment biotechnology next year, with companies including Moderna (MRNA.US), Merck (MRK.US), and AstraZeneca (AZN.US) expected to announce key trial data.

Over the past year, Moderna has made headlines due to its collaboration with Merck in developing the personalized cancer vaccine mRNA-4157 (V940). In June this year, Moderna and Merck announced positive data from a combination therapy for treating lethal skin cancer over nearly three years at the American Society of Clinical Oncology (ASCO) annual meeting. It is reported that in a mid-term trial for patients with surgically removed high-risk melanoma (stage III/IV), Moderna's personalized cancer vaccine mRNA-4157 (V940) combined with Merck's PD-1 inhibitor Keytruda improved patient survival rates and showed lasting efficacy. Morgan Stanley Analyst Terence Flynn pointed out that Moderna is awaiting the key phase II interim data for this melanoma combination therapy in the fourth quarter of 2025/2026.

Meanwhile, Moderna's competitor BioNTech (BNTX.US) hopes to release the phase II interim data of its cancer vaccine BNT122 in adjuvant therapy for colorectal cancer by the end of 2025, and another interim data regarding the lack of progression-free survival impact of BNT122 on patients with metastatic melanoma is expected to be announced next year.

In terms of antibody-drug conjugates, AstraZeneca and its Japanese partner Daiichi Sankyo are awaiting the phase III data for AVANZAR treating non-small cell lung cancer in the second half of 2025 for Datopotamab Deruxtecan (Dato-DXd).

The phase III data of the Trodelvy + Pembro combination obtained from the EVOKE-03 study by Gilead Sciences (GILD.US) is expected to be announced in the second half of 2025 or the first half of 2026, while Pfizer (PFE.US) will announce early trial data of its antibody-drug conjugate sigvotatug vedotin.

In the PD-(L)1×VEGF dual antibody category, Summit Therapeutics (SMMT.US) is awaiting the data from next year's trials of the candidate drug HARMONi and HARMONi-2 — this company challenges Merck's dominant position in lung cancer therapies with its collaboratively developed ivonescimab alongside the Chinese biotechnology company Akeso (AKESF.US). BioNTech is expected to announce the interim data of the PD-(L)1×VEGF dual antibody BNT327 for treating small cell lung cancer and triple-negative breast cancer in 2025.

Other key trial data worth noting includes the Phase 3 data of Vepdegestrant, a protein degradation agent jointly developed by Pfizer and Arvinas (ARVN.US), in the VERITAC-2 trial for locally advanced or metastatic ER+/HER2- breast cancer, which is expected to be released in the first quarter of 2025.

Meanwhile, Regeneron Pharmaceuticals (REGN.US) is awaiting Phase 3 data for its LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo in the treatment of first-line metastatic melanoma next year. BioNTech is expected to release its Phase 3 updated data for its anti-CTLA-4 candidate antibody BNT316 in the treatment of NSCLC.

In the area of anti-Tigit therapies, Merck is awaiting Phase 3 data for MK-7684A as a first-line combination treatment for non-small cell lung cancer, and in a head-to-head treatment against SCLC with Roche's Tecentriq. Meanwhile, another anti-Tigit therapy developed by Gilead Sciences and Arcus Biosciences (RCUS.US), domvanalimab, will obtain mid and late-stage data for gastric cancer and gastrointestinal cancer from EDGE-Gastric and STAR-221 in 2025 and the second half of 2025 respectively.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment